Abstract
This article reviews recent evidence on changes over time in the direct medical costs of treating three of the more common mental health disorders in the US: the acute (16-week) phase of major depressive disorder, the ongoing treatment of schizophrenia, and the ongoing treatment of bipolar I disorders. The three studies discussed in this article cover various time intervals over the decade from 1991 through 2000, and encompass both private sector and governmental funding sources. Although there has been a shift over time away from intensive psychosocial/psychotherapy and towards increasingly expensive psychopharmacotherapy for all three disorders, total direct medical costs of treatment for each of these three mental health disorders have been declining over time. However, a substantial portion of treatment is not supported by clinical evidence.
Similar content being viewed by others
References
McKusick DT, Mark TL, King E, et al. Spending for mental health and substance abuse treatment, 1996. Health Affairs 1996; 17 (5): 147–57
Duggan MG. Does Medicaid pay too much for prescription drugs? A case study of atypical antipsychotics. Cambridge (MA): National Bureau of Economic Research, 2003 Apr. Working Paper No. 9626
Croghan TW. The controversy of increased spending for antidepressants. Health Affairs 2001; 20 (2): 129–35
Hanson KL. Public opinion and the mental health parity debate. Lessons from the survey literature. Psychiatric Serv 1998; 49 (8): 1059–66
Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and twelvemonth prevalence of DSM-III-R psychiatric disorders in the United States. Results from the national comorbidity survey. Arch Gen Psychiatry 1994; 51 (1): 8–19
Keller MB, Berndt ER. Depression treatment. A life-long commitment? Psychopharmacol Bull 2002; 36 (2): 1–9
Berndt ER, Bir A, Busch SH, et al. The medical treatment of depression, 1991–1996. Productive inefficiency, expected outcome variations, and price indexes. J Health Econ 2002; 21: 373–96
Frank RG, Busch SH, Berndt ER. Measuring prices and quantities of treatments for depression. Am Econ Rev 1998; 88 (2): 106–11
Frank RG, Berndt ER, Busch SH. Price indexes for the treatment of depression. In: Triplett JE, editor. Measuring the prices of medical treatments. Washington, DC: Brookings Institution Press, 1999: 72–102
Berndt ER, Cutler DM, Frank RG, et al. Medical care prices and output. In: Newhouse JP, Culyer AC, editors. Handbook of health economics. Vol. 1A. Amsterdam: Elsevier Science BV, 2000: 119–80
Lehman AF. Quality of care in mental health. The case of schizophrenia. Health Aff 1999; 18 (5): 52–65
Lehman AF, Steinwachs DS. Translating research into practice. The schizophrenia patient outcomes research team (PORT) recommendations. Schizophr Bull 1998; 24 (1): 1–10
Lehman AF, Steinwachs DS, and the Survey Co-Investigators of the PORT Project. Patterns of usual care for schizophrenia. Initial results from the schizophrenia patient outcomes research team (PORT) client survey. Schizophr Bull 1998; 24 (1): 11–9
Frank RG, Berndt ER, Busch AB, et al. Quality-constant ‘prices’ for the ongoing treatment of schizophrenia. An exploratory study. Qtrly Rev Econ and Bus. 44 (3), July 2004: 390–409
Rosenheck RA, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. A randomised controlled trial. JAMA 2003; 290 (20): 2693–702
Berndt ER. Trends and drivers of expenditures on psychotropic drugs in the US Presentation at the National Institute of Mental Health Pharmacoeconomics Research Workshop, Bethesda MD, 23 May 2002
Frank RG, Conti R. Mental health policy and psychotropic drugs. Issue paper, Sub-Committee on Psychiatric Medications of the President’s Mental Health Commission. Washington, DC: 2004 Jan 24
Ling DYC, Busch AB, Frank RG. Treatment price indexes for bipolar disorder [poster]. Presented at the National Institute of Mental Health, Economics of Mental Health Workshop; 2002 Sep 24; Bethesda. Updated, 8 July 2004
American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002; 159 (4 Suppl.): 1–50
Acknowledgements
The research findings reported here reflect collaborations with a number of coauthors. Research support is gratefully recognised in the acknowledgements portion of the various papers and articles reviewed herein.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Berndt, E.R. Changes in the costs of treating mental health disorders. Pharmacoeconomic 22 (Suppl 2), 37–50 (2004). https://doi.org/10.2165/00019053-200422002-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200422002-00005